Hamdan Medical Journal (previously the Journal of Medical Sciences)

Table of Contents  

THl/TH2 Cytokine Fingerprinting for Probing Diseases: From the Bench to the Clinic

Mohamed L Salem, David J. Cole
Published in : Journal of Medical Sciences ; Vol 1, No 2 (2008)
DOI : 10.2174/1996327000801020021

Abstract


Cytokines play crucial roles in all aspects of health and diseases. They influence immune expression, the development of immunologic memory, and regulation of antigen-specific and nonspecific immune activation. Based on their production by T helper (TH) cells, cytokines are categorized into TH1 and TH2 types. TH1 type includes inflammatory cytokines and growth factors. The former induces signal three that bridge innate and adaptive immunity, whilst the latter sustains proliferation and survival of T cells. Therefore, TH1 cytokines profoundly mediate generation of preventive immune responses toward infectious diseases and cancer. By contrast, TH2 cytokines are anti-inflammatory through suppression of THl-mediated immune responses, but they also accelerate TH2-mediated diseases. This article describes the impact of the THl/TH2 cytokines on shaping the nature of the immune cell responses to inflammation, infection, and cancer. We predict that THl/TH2 could be considered as a fingerprint for probing the identity of diseases. Fundamental knowledge of the design of cytokine-based therapeutic strategies is now reaching the phase of application and a number of cytokines are already on the market and many others are under clinical investigation.


Keywords


Cytokines; THl; TH2; inflammation; antiinflammatory

View article in  :   PDF    

References


Moss RB, Moll T, El-Kalay M, Kohne C, Soo Hoo W,Encinas J, et al. Thl/Th2 cells in inflammatory disease states: therapeutic implications. Expert Opin Biol Ther 2004; 4: 1887-1896.

Chamoto K, Kosaka A, Tsuji T, Matsuzaki J, Sato T,Takeshima T, et al. Critical role of the Thl/Tcl circuit for the generation of tumor specific CTL during tumor eradication in vivo by Thl-cell therapy. Cancer Sci 2003;94: 924-928.

Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A,Morel PA, et al. Dendritic cells mediate NK cell help for Thl and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol 2003;171: 2366-2373.

Salem ML. Estrogen, a double-edged sword: modulation of THl- and TH2-mediated inflammations by differential regulation ofTHl/TH2 cytokine production. Curr Drug Targets Inflamm Allergy 2004; 3: 97-104.

Piccinni MP, Scaletti C, Maggi E, Romagnani S. Role of hormone-controlled Thl- and Th2-type cytokines in successful pregnancy. J Neuroimmunol 2000; 109: 30-33.

Whary MT, Fox JG. Thl-mediated pathology in mouse models of human disease is ameliorated by concurrentTh2 responses to parasite antigens. Curr Top Med Chem 2004; 4: 531-538.

Nakamura Y, Hoshino M. TH2 cytokines and associated transcription factors as therapeutic targets in asthma.Curr Drug Targets Inflamm Allergy 2005; 4: 267-270.

Adams G, Vessillier S, Dreja H, Chernajovsky Y. Targeting cytokines to inflammation sites. Nat Biotechnol 2003;21: 1314-1320.

Dinarello CA. Anti-cytokine therapeutics and infections.Vaccine 2003; 21 Suppl 2: S24-34.

Andreakos ET, Foxwell BM, Brennan FM, Maini RN,Feldmann M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev 2002; 13: 299-313.

Scott P, Pearce E, Cheever A W, Coffman RL, Sher A. Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev, 1989;112: 161-182.

Grab DJ, Salim M, Chesney J, Bucala R, Lanners HN.A role for peripheral blood fibrocytes in Lyme disease? Med Hypotheses, 2002; 59: 1-10.

Elenkov IJ, Jezzoni DG, Daly A, Harris AG, Chrousos GP.Cytokine dysregulation, inflammation and well-being.Neuroimmunomodulation 2005; 12: 255-269.

Salem ML, Hossain MS, Nomoto K. Mediation of the immunomodulatory effect of beta-estradiol on inflammatory responses by inhibition of recruitment and activation of inflammatory cells and their gene expression of TNF-alpha and IFN-gamma. Int Arch Allergy Immunol 2000; 121: 235-245.

Salem ML, Matsuzaki G, Madkour GA, Nomoto K.Beta-estradiol-induced decrease in IL-12 and TNF-alpha expression suppresses macrophage functions in the course of Listeria monocytogenes infection in mice. Int J Immunopharmacol 1999; 21: 481-497.

Salem ML, Matsuzaki G, Nomoto K. Beta-estradiolinduced inhibition of macro phages function during Listeria monocytogenes infection. The Winter Advanced Course for Immunology and Infectious Diseases(WACIID)’1994” Tokyo, Japan. 1994.

Chaouat G, Ledee-Bataille N, Dubanchet S, Zourbas S,Sandra O, Martal J. THl/TH2 paradigm in pregnancy:paradigm lost? Cytokines in pregnancy/early abortion:reexamining the THl/TH2 paradigm. Int Arch Allergy Immunol 2004; 134: 93-119.

Nath N, Giri S, Prasad R, Salem ML, Singh AK, Singh I. 5-aminoimidazole-4-carboxamide ribonucleoside:a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J Immunol 2005; 175: 566-574.

Salem ML, Kishihara K, Abe K, Matsuzaki G, Nomoto K. N-3 polyunsaturated fatty acids accentuate B16 melanoma growth and metastasis through suppression of tumoricidal function ofT cells and macrophages.Anticancer Res 2000; 20: 3195-3203.

Salem ML. Systemic treatment with n-6 polyunsaturated fatty acids attenuates EL4 thymoma growth and metastasis through enhancing specific and non-specific anti-tumor cytolytic activities and production of TH1 cytokines. Int Immunopharmacol, 2005; 5: 947-960.

Reiner SL, Locksley RM. Cytokines in the differentiation of Thl/Th2 CD4+ subsets in leishmaniasis. J Cell Biochem 1993; 53: 323-328.

Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic,and inflammatory diseases. Clin Microbiol Rev 1996; 9:532-562.

Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54: 721-728.

Argiles JM, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev 1999; 19: 223-248.

Sun S, Zhang X, Tough DF, Sprent J. Type I interferonmediated stimulation of T cells by CpG DNA. J Exp Med 1998; 188: 2335-2342.

Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, Barth RJ, et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type 1 IFN. J Exp Med, 2004; 199: 775-784.

Salem ML, Kadima A, EL-Naggar S, Rubinstein MM,Gillanders WE, Cole DJ. Defining the antigen-specific Tcell response to vaccination and poly(I:C)/TLR3 signaling:evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunotherapy 2005; 28(3): 220-8.

Salem ML, Kadima A, EL-Naggar S, Gillanders WE, Cole DJ. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu.Vaccine 2006; 24(24): 5119-32.

Bathe OF, Dalyot-Herman N, Malek TR. IL-2 during in vitro priming promotes subsequent engraftment and successful adoptive tumor immunotherapy by persistent memory phenotypic CD8( +) T cells. J Immunol 2001;167: 4511-4517.

Zou JP, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH, et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 1995; 7: 1135-1145.

Schluns KS, Kieper WC, Jameson SC, Lefrancois L.Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat Immunol, 2000; 1:426-432.

Fry TJ, Mackall CL. Interleukin-7: from bench to clinic.Blood, 2002; 99: 3892-3904.

Rizza P, Ferrantini M, Capone I, Belardelli F. Cytokines as natural adjuvants for vaccines: where are we now? Trends Immunol 2002; 23: 381-383.

Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 2002; 23: 201-208.

Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296-306.

Murtaugh MP, Foss DL. Inflammatory cytokines and antigen presenting cell activation. Vet Immunol Immunopathol 2002; 87: 109-121.

Mihich E. On the immunomodulating effects of anticancer drugs and their therapeutic exploitation. Jpn J Clin Oncol 2000; 30: 469-471.

Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J Surg Oncol 1998; 68: 122-138.

Mitchell MS. Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2. Semin Oncol 1992; 19: 80-87.

Mitchell MS. Combinations of anticancer drugs and immunotherapy. Cancer Immunol Immunother 2003;52: 686-692.

Mitchell MS. Immunotherapy as part of combinations for the treatment of cancer. Int Immunopharmacol 2003; 3:1051-1059.

Mihalyo MA, Doody AD, McAleer JP, Nowak EC, Long M, Yang Y, et al. In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy. J Immunol 2004; 172: 5338-5345.

Zagozdzon R, Golab J. Immunomodulation by anticancer chemotherapy: more is not always better (review). IntJ Oncol, 2001; 18: 417-424.

Dueñas-Gonzalez A, Verastegui E, Lopez-Graniel C,Gonzalez A, Mota A, Barrera-Franco JL, et al. A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma. Int Immunopharmacol 2002; 2: 1007-1016.

Hadden JW. Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol 2003; 3: 1061-1071.

Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother 2005; 28: 220-228.

Salem ML, Kadima AN, Zhou Y, Nguyen CL, Rubinstein MP, Demcheva M, et al. Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine.J Immunol 2004; 172: 5159-5167.

Salem ML, EL-Naggar SA, Kadima A, Diaz-Montero M, Gillanders WE, Cole DJ. Cyclophosphamide preconditioning enhances the antigen-specific CD8+T cell responses to peptide vaccination: evidence of enhanced innate immunity and induction of a beneficial cytokine milieu. 5th Annual Research Retreat Citadel,Charleston, SC, USA. 2005.

Ehrke MJ. Immunomodulation in cancer therapeutics. Int Immunopharmacol 2003; 3: 1105-1119.

Hadden J, Verastegui E, Barrera JL, Kurman M, Meneses A, Zinser JW, et al. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int Immunopharmacol 2003; 3: 1073-1081.

Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D,Clancy M, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFNgamma induction is associated with clinical response.Clin Cancer Res 2000; 6: 1678-1692.

Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC,Topalian SL, et al. Adoptive transfer of cloned melanomareactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001; 24: 363-373.

Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 2002; 298: 850-854.

Dudley ME, Wunderlich JR, Yang JC, Hwu P,Schwartzentruber DJ, Topalian SL, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002;25: 243-251.

Villinger F. Cytokines as clinical adjuvants: how far are we? Expert Rev Vaccines, 2003; 2: 317-326.

Ikeda K, Kobayashi M, Saitoh S, Someya T, Hosaka T, Akuta N, et al. Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study. J Gastroenterol Hepatol 2005; 20: 95-102.

Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.Cancer Immunol Immunother 2005: 1-11.

von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001; 7: 1181-1191.

Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. Toxicol Pathol,1999; 27: 58-63.

Rochlitz CF. Gene therapy of cancer. Drugs Today (Bare)2000; 36: 619-629.

Smith AE. Viral vectors in gene therapy. Annu Rev Microbiol 1995; 49: 807-838.

Ferrantini M, Belardelli F. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin Cancer Biol 2000; 10:145-157.

Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M, et al. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Mol Ther 2002; 5: 609-616.

Maheshwari A, Han S, Mahato RI, Kim SW. Biodegradable polymer-based interleukin-12 gene delivery: role of induced cytokines, tumor infiltrating cells and nitric oxide in anti-tumor activity. Gene Ther 2002; 9: 1075-1084.

Shi F, Rakhmilevich AL, Heise CP, Oshikawa K, Sondel PM, Yang NS, et al. Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol Cancer Ther 2002; 1: 949-957.

Baca-Estrada ME, Foldvari M, Ewen C, Badea I, Babiuk LA. Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system. Vaccine 2000; 18: 1847-1854.

Hancock GE, Smith JD, Heers KM. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12. Viral Immunol 2000; 13:57-72.

Wang S, Uu X, Caulfield MJ. Adjuvant synergy in the response to hepatitis B vaccines. Vaccine 2003; 21:4297-4306.

Mullerad J, Cohen S, Benharroch D, Apte RN. Local delivery of IL-l alpha polymeric micro spheres for the immunotherapy of an experimental fibrosarcoma.Cancer Invest 2003; 21: 720-728.

Mullerad J, Cohen S, Voronov E, Apte RN. Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin 1 via biodegradable microspheres. Cytokine 2000; 12: 1683-1690.

Egilmez NK, Jong YS, Hess SD, Jacob JS, Mathiowitz E, Bankert RB. Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SClD-Winn model. J Immunother 2000; 23: 190-195.

Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E,Bankert RE. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 2000; 60: 3832-3837.

Eguchi J, Hiroishi K, Ishii S, Mitamura K. Interferon-alpha and interleukin-12 gene therapy of cancer: interferonalpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing. Cancer Immunol Immunother 2003; 52: 378-386.

Koten JW, Van Luyn MJ, Cadée JA, Brouwer L, Hennink WE, Bijleveld C, et al. IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. Cytokine 2003; 24: 57-66.

Oettinger C, D’Souza M. Microencapsulation of tumor necrosis factor oligomers: a new approach to proinflammatory cytokine inhibition. J Interferon Cytokine Res 2003; 23: 533-543.

Zhou S, Deng X, He S, Li X, Jia W, Wei D, et al. Study on biodegradable microspheres containing recombinant interferonalpha-2a. J Pharm Pharmacol 2002; 54:1287-1292.

Cole DJ, Gattoni-Celli S, McClay EF, Metcalf JS, Brown JM, Nabavi N, et al. Characterization of a sustainedrelease delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix. Clin Cancer Res 1997; 3: 867-873.

Cole DJ, Connolly RJ, Chan MW, Schwaitzberg SD,Byrne TK, Adams DB, et al. A pilot study evaluating the efficacy of a fully acetylated poly N-acetyl glucosamine membrane formulation as a topical hemostatic agent.Surgery 1999; 126: 510-517.

Nguyen CL, Salem ML, Rubinstein MP, Demcheva M,Vournakis JN, Cole DJ, et al. Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine 2003; 21: 2318-2328.

Salem ML, El-Naggar S, Kadima AN, Vournakis JN,Cole DJ, Gillanders WE. Novel non-viral delivery system enhances the efficacy of DNA vaccines targeting cytotoxic T lymphocytes. 4th Annual Research Retreat, November 11th, Charleston, SC, USA. 2004.





Add comment 





Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA